Monthly Archives: April 2011

Should Doctors Shoulder Healthcare Costs?

As the debate over the rising costs of new drug R&D and brand name medications rages on, physicians are increasingly doing their part to minimize collateral damage inflicted upon the patient. A new report from Bain & Company — The new cost-conscious doctor: changing America’s healthcare landscape — reveals that, increasingly, physicians believe that part […]
Posted in healthcare | Tagged , , , , , | Leave a comment

Lives of Patients Keep Sales Reps off Life Support

Pharm Exec’s sister conferencing unit explores the future of the US sales rep, including the implications of GSK’s new value-based compensation model Last week brought a small but dedicated group of sales professionals to a CBI conference in San Diego with a clear mandate: to rate the future of the “detail man” — dead or […]
Posted in Sales | Tagged , , , , | Leave a comment

Inspector General Puts Forest CEO in the Crosshairs

Forest Laboratories’ CEO Howard Solomon was no doubt surprised to receive a form letter from the Office of Inspector General (OIG) on April 8, which, if acted upon, would exclude him from doing business with federal healthcare plans, including Medicare and Medicaid. Solomon has 30 days to explain to the OIG why he should not […]
Posted in Strategy | Tagged , , , , , , , | Leave a comment

California Life Sciences to Partner with China

BIOCOM, a trade group representing Southern California’s life sciences industry, is ramping up partnership efforts in China to meet an emerging desire for novel drug therapies. While intellectual property (IP) protections and the Chinese government’s willingness to pay for expensive new products represent two large and lingering question marks, Joe Panetta, president and CEO at […]
Posted in Biotech, Emerging Markets, Global, IP, leadership, Market Access, R&D | Tagged , , , , | Leave a comment
  • Categories

  • Meta